Weekly InjectableAims: To understand patient preferences for once-daily oral vs. once-weekly injectable Type 2 Diabetes Mellitus (T2DM) medication administration profiles, and reasons for their preferences. Materials and methods: The REVISE study, a cross-sectional online survey of 600 participants ...
Research shows an average weight loss of 8% to 15% within 12 to 18 months of starting an injectable medication. They can also treat health problems such as type 2 diabetes. What Are the Side Effects and Risks of Injectable Weight-Loss Medications? The most common side effects include nausea...
Semaglutide (sold as Wegovy) was FDA approved in 2021. It is a once-weekly injection used along with a reduced-calorie diet. Both medications were initially approved to treat type 2 diabetes. The new indications include treatment of obesity (BMI > 30) without diabetes and in adults with aBM...
The once-weekly, injectable medication is approved at a dose of 2.4 mg for this indication. "Today's approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program," said John Sharretts, MD, of the FDA's Center for Drug Ev...
This study explored the barriers that adult Americans experience when taking injectable medications for type 2 diabetes, from the time of filling the initial prescription through the decision to discontinue the medication. An Internet-based survey was conducted in 2 waves among adult patients (N = ...
A 28-week open-label (oral medication blinded), comparator-and placebo-controlled trial was conducted to compare the safety and efficacy of BYDUREON BCISE to sitagliptin and placebo in adult patients with type 2 diabetes whose glycemic control was inadequate with metformin therapy (Trial 2 NCT016527...
Our Erzofri (paliperidone palmitate) Extended-Release Injectable Suspension, for Intramuscular Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. This is not a complete list of side effects and others may ...
With the publication of the ADA’s2018 Standards of Medical Care in Diabetescame a major addition to the Antihyperglycemic Therapy decision protocol: a GLP-1 as additional agent to reduce risk of death or major adverse cardiovascular complications for patients with established ASCVD, ...
“Victoza is an effective GLP-1 receptor agonist in the treatment of Type 2 diabetes. However, it’s daily dosing and lower HbA1c reductions than other weekly-dosed GLP-1 receptor agonists make it a less popular choice overall.” Jennie Stanford, M.D., FAAFP, DipABOMFAMILY PHYSICIAN & OBE...
Shortages of injectable semaglutide (Novo Nordisk), sold under trade names Ozempic (for type 2 diabetes with or without established CVD) and Wegovy (for overweight or obesity), are forcing clinicians to look to alternatives when managing patients who need the medication. Semaglutide and other ...